Why BioNTech Stock Crushed the Market Today

BioNTech (NASDAQ: BNTX), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on Friday. Investors clearly liked what they heard, as they traded up the German biotech's American depositary receipts (ADRs) by 10% that day.BioNTech and Chinese peer Duality Biologics announced before market open that a phase 3 clinical trial of their cancer drug trastuzumab pamirtecan met its primary endpoint of progression-free survival. The medication was administered to patients with unresectable or metastatic breast cancer who had previously received certain types of chemotherapy.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool